Compromised immune status could have effects on disease.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Continued investigation of Richter transformation may be warranted as new CLL treatments emerge.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.